Navigation Links
Cordex Completes Production of ATPace(TM) Clinical Trial Material
Date:6/29/2009

LA JOLLA, Calif., June 29 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has successfully completed the production of the ATPace(TM) clinical trial material (CTM) in preparation for planned pivotal clinical trials. The protocol of these clinical trials has been approved by the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment process.

ATPace(TM) is a novel, proprietary, stable, injectable formulation of adenosine 5'-triphosphate (ATP) under development as a therapeutic and diagnostic drug for the management of cardiac arrhythmias. A stable liquid formulation of ATP is a prerequisite for ATPace(TM)'s clinical superiority over adenosine, the only approved competition in the U.S. The maintenance of intact ATP molecules in solution is critical for the unique bradycardic effects of ATP, in particular its blockade of atrio-ventricular nodal conduction. Cordex has filed a formulation patent covering this stable liquid formulation of ATP for intravenous administration.

The ATPace(TM) CTM was produced off-site by a U.S. manufacturer of sterile injectable products under the regulatory supervision of Cordex and Cato Research, Inc. The CTM will be used in the planned clinical trials for the acute treatment of patients presenting with paroxysmal supraventricular tachycardia (PSVT) in the emergency room.

Several formulations of ATP have been used in Europe for over five decades as the drug of choice for the acute conversion of PSVT to normal sinus rhythm. During this extended period of use, ATP manifested an excellent safety and efficacy profile. Cordex intends to use clinical data obtained in Europe as a part of the ATPace(TM)'s NDA under section 505b(2).

"We are pleased to reach this important milestone in the development program of ATPace(TM)," said Amir Pelleg, Ph.D., Cordex's President and CSO. "Together with Cato Research,
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cordex Pharma Forms Heart Failure Medical Advisory Board
2. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
3. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
4. Brooks Instrument Completes Acquisition of Celerity's Instrumentation Division
5. Sinovac Completes Construction of H1N1 Virus Seed Bank
6. Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease
7. Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
8. Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108
9. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
10. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
11. NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Research and Markets  has announced the addition ... Application, Geography - Global Analysis and Forecast (2014 - ... Organic electronics, also called as polymer electronics or plastic ... with small conductive molecules and electrically conductive polymers. It ... are carbon based, made using synthetic strategies developed in ...
(Date:10/20/2014)... Convey Computer , the leader ... Iowa State University won first place in the ... HC-2ex, the team’s solution achieved the highest overall performance ... second place finisher. , Experts from all segments of ... long challenge, using a variety of design tools, hardware ...
(Date:10/20/2014)... -- GenVec, Inc. (NASDAQ: GNVC ) today announced the ... board of directors effective on October 24, 2014.   Dr. Horovitz ... its chairman from June 2006 to November 2013.  During his ... and Audit Committees of the board.  "We ... service to GenVec, and its stockholders," said Wayne T. ...
(Date:10/20/2014)... 20, 2014 Local veterinary surgeon, Dr. ... investigational study of donor stem cells for dogs with ... therapy and has performed clinical stem cell therapy for ... to determine if a single injection of donor stem ... help reduce pain and inflammation in the treated joints. ...
Breaking Biology Technology:Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... INDIANAPOLIS, Feb. 8 Semafore Pharmaceuticals Inc.,today announced ... and Ullrich Schwertschlag, M.D., Ph.D., chief medical officer,will ... programs at,2:45 p.m. EST on Wednesday, Feb. 13, ... New York City., The update will include ...
... onTargetjobs, the leading,niche Internet job ... of,RegionalHelpWanted.com, a network of over 350 ... is the parent company of BioSpace.com, ... career services to the biotechnology, pharmaceutical,hospitality, ...
... Remain as Advisor to Company, FRAZER, Pa., Feb. ... Executive Vice President, General Counsel &,Secretary, John E. Osborn, ... March 31. Mr. Osborn has agreed to remain as ... matters., "John has been an invaluable member of ...
Cached Biology Technology:Semafore to Present at BIO CEO & Investor Conference 2onTargetjobs Announces Acquisition of RegionalHelpWanted.com 2Cephalon General Counsel John E. Osborn to Resign Position 2Cephalon General Counsel John E. Osborn to Resign Position 3
(Date:10/15/2014)... Gutenberg University Mainz (JGU) as a full member, ... maintain a significant nationwide standing in the field ... Johannes Gutenberg University Mainz as a full member ... national and international competition for the best minds ... be proud that Mainz University has been recognized ...
(Date:10/15/2014)... linked increased resistance to bacterial pneumonia in female mice ... estrogen. , Females are naturally more resistant to respiratory ... has shown that increased resistance to bacterial pneumonia in ... synthase 3 (NOS3). They also show that this enzyme ... sex hormone estrogen. , The team, lead by Professor ...
(Date:10/15/2014)... Geneticist Fred Alt will be awarded the 44th Rosenstiel ... University for his pioneering research exploring the mechanisms of ... and cancer cells. Alt is the second alumnus to ... the Nobel Prize in 2003. , Alt is the ... Genetics at Harvard Medical School and an investigator at ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... bonds that tie a mother to her newborn may be ... deliver by cesarean section, according to a study published by ... Journal of Child Psychology and Psychiatry . ... James Swain, M.D., recruited two groups of parents from postpartum ...
... This press release is available in German . ... checks above all at airports has been increased ... protection of passengers. Possibilities for new and safe methods of ... can be used for this purpose, however, it has to ...
... into the mating and nesting practices of a common ... males sequentially the highest recorded of any vertebrate. ... Biological Sciences, has researched the frog species Bibron,s toadlet ... field trip, discovered a new behaviour undetected in a ...
Cached Biology News:Natural childbirth linked to stronger baby bonding than C-sections 2Checking people at airports -- with terahertz radiation 2Australian frog species chooses not to put eggs in 1 basket 2
A Highly Purified, Cost-Effective Taq DNA Polymerase...
... , Ellman's reagent *M: ... *Storage: RT, When an enzyme-catalyzed reaction ... present in the substrate, it may be possible ... with the product to form a chromophore. The ...
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... a recombinant human protein produced in E. coli ... RNase A type enzymes. The mode of ... in a 1:1 ratio. The enzyme has been ... and cell types. Addition of the ribonuclease inhibitor ...
Biology Products: